Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Empagliflozin
Drug ID BADD_D00765
Description Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.[A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects.[A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014.[A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Indications and Usage Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Marketing Status Prescription
ATC Code A10BK03
DrugBank ID DB09038
KEGG ID D10459
MeSH ID C570240
PubChem ID 11949646
TTD Drug ID D06ALD
NDC Product Code 12714-201; 71796-001; 65727-085; 49629-033; 76072-1015; 0597-0152; 49629-034; 62756-159; 0597-0153; 55154-0412; 71610-177; 50090-4384; 59651-179; 50090-4492; 70518-2447; 46708-903; 42765-016; 67835-0024; 55154-0411; 69766-036; 69037-0029; 69766-052; 70518-1986
Synonyms empagliflozin | 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene | BI 10773 | BI10773 | BI-10773 | Jardiance
Chemical Information
Molecular Formula C23H27ClO7
CAS Registry Number 864070-44-0
SMILES C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Starvation14.03.02.0250.000195%Not Available
Vaginal lesion21.08.02.0170.001123%Not Available
Groin infection15.03.02.017; 11.01.08.0550.000749%Not Available
Urine albumin/creatinine ratio increased13.13.01.0310.000749%Not Available
Blood ketone body13.02.04.0080.002994%Not Available
Blood ketone body increased13.02.04.0090.012352%Not Available
Blood ketone body present13.02.04.0100.004117%Not Available
Urine ketone body13.02.04.0140.005989%Not Available
Diabetic foot24.04.03.015; 23.07.03.008; 17.09.04.006; 14.07.06.001; 05.07.06.0010.002246%Not Available
Genital infection bacterial21.10.03.016; 11.02.01.0410.001123%Not Available
Purulence11.01.08.0600.001123%Not Available
Multimorbidity08.01.03.0750.000195%Not Available
Apparent death08.01.03.0620.000749%Not Available
Autoimmune pancreatitis10.04.08.010; 07.18.01.0090.000749%Not Available
Diabetic metabolic decompensation14.07.03.003; 05.07.03.0030.000749%Not Available
Hyperosmolar hyperglycaemic state17.02.04.020; 14.07.04.006; 05.07.04.0060.001872%Not Available
The 17th Page    First    Pre   17    Total 17 Pages